<p>/PRNewswire/ -- 中國九洲大藥房公司（Nasdaq:CJJD）（&#34;九洲大藥房&#34;或&#34;公司&#34;）是一家領先的線上和線下零售商、藥品及其他健康產品的批發分銷商以及中國的醫療服務提供者，今天宣佈已達成戰略重組計劃的最終協議，以轉型為輕資產、以批發為重點的公司，精簡運營並提升盈利能力。</p>
<p>此次重組涉及兩項主要交易（&#34;交易&#34;）：</p>
<ul>
<li>收購交易：通過發行 2,225,000 股普通股進行股權交換，收購快速成長的藥品批發公司 Allright（杭州）互聯網科技有限公司（&#34;Allright&#34;），這代表了交易完成後公司已發行和流通普通股的 38%；以及</li>
<li>剝離交易：將九洲大藥房的藥品零售業務出售給現任首席執行官兼董事劉雷和董事李琦，他們及其關聯方目前共同持有公司約 41% 的流通普通股，作為交換，劉、琦及其關聯方將向公司交回其持有的共計 2,548,353 股普通股。</li>
</ul>
<p>預計交易將在 2025 年第一季度完成，需滿足包括九洲大藥房股東批准在內的慣常成交條件。交易完成後，劉和琦預計將辭去公司董事會及其他任何職務（包括首席執行官），而 Allright 的最終股東孔靈濤將加入董事會。各方同意，公司的現任首席財務官趙峯將擔任臨時首席執行官，以確保業務的持續運營和 Allright 業務的整合。</p>
<p>九洲大藥房董事長兼首席執行官劉雷先生評論道：&#34;此次重組標誌着 CJJD 的一個關鍵時刻，我們將從高成本的零售領域轉型為以批發為重點的模式。雖然我將把重心轉向我深耕的零售業務，但我相信這一轉型將提升運營效率，併為 CJJD 的股東創造長期價值。我期待在新領導下看到批發業務蓬勃發展。&#34;</p>
<p>Allright 的最終股東及即將加入董事會的孔靈濤先生表示：&#34;我很高興能與 CJJD 攜手共建更強大的批發平台。Allright 的增長軌跡與 CJJD 的戰略願景高度契合，我相信我們的專業結合將為藥品批發市場創造新的擴展和成功機會。&#34;</p>
<p>現任首席財務官及即將擔任臨時首席執行官的趙峯先生補充道：&#34;在這個轉型時期，我很榮幸能擔任臨時首席執行官。我想感謝劉先生在將 CJJD 建設成今天這樣強大公司的領導和奉獻。隨着我們向以批發為驅動的模式轉型，我期待與孔先生及我們的團隊緊密合作，執行我們的戰略願景，確保 Allright 業務的無縫整合。我們的重點將繼續放在加強批發業務、提高效率，併為 CJJD 的長期成功奠定基礎。&#34;</p>
<p><strong>關於中國九洲大藥房公司</strong></p>
<p>中國九洲大藥房公司（&#34;九洲大藥房&#34;或&#34;公司&#34;）是一家領先的線上和線下零售商及藥品和其他健康產品的批發分銷商，同時也是中國的醫療服務提供者。九洲大藥房目前運營着一家在線藥房和零售藥店，現場有持證醫生提供諮詢、檢查和常見疾病的治療。它也是類似於其藥房所銷售產品的批發分銷商。有關公司的更多信息，請訪問 http://jiuzhou360.com。公司定期在其網站上發佈重要信息。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含關於公司未來預期、計劃和前景的信息，這些信息構成了 1995 年美國私人證券訴訟改革法案、1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條所定義的前瞻性聲明。新聞稿中除歷史事實聲明外的所有聲明，包括關於擬議交易的好處和預計完成時間的聲明，均為前瞻性聲明。這些前瞻性聲明中的一些可以通過使用前瞻性詞彙來識別，包括 “可能”、“應該”、“期望”、“打算”、“將”、“估計”、“預期”、“相信”、“預測”、“計劃”、“目標”、“項目”、“可以”、“會”、“將”、“繼續”、“預測” 或這些術語的否定形式或變體或類似表達。所有前瞻性聲明均基於估計、預測和假設，儘管公司及其管理層認為這些是合理的，但本質上是不確定的。實際結果可能因多種因素而與歷史結果或這些前瞻性聲明所指示的結果有重大差異，包括但不限於與公司及時完成交易或根本無法完成交易的能力、實施其商業計劃和戰略的能力、籌集額外資金的能力、維持和發展其業務的能力、批發定價和藥品需求的波動、經營結果的變化、維持和提升品牌的能力、新產品和服務的開發和推出、成功整合收購的公司、技術和資產到其產品和服務組合中的能力、市場營銷和其他業務發展舉措、與供應商和醫療服務提供者的關係、行業競爭、一般政府監管、經濟狀況、對關鍵人員的依賴、吸引、招聘和留住具備滿足客户要求的技術技能和經驗的人員的能力，以及保護其知識產權的能力。公司鼓勵您查看可能影響其未來結果的其他風險因素，這些因素在公司的年度報告和向證券交易委員會（“SEC”）的其他文件中有所披露。</p>
<p>您不應對前瞻性聲明過度依賴，這些聲明僅在作出時有效。公司不保證合併後的公司將實現其預期結果。除法律另有要求外，公司不承擔更新這些前瞻性聲明的義務。</p>
<p><strong>關於擬議交易的重要信息及獲取途徑</strong></p>
<p>本新聞稿涉及與九洲大藥房相關的某些擬議交易。公司將向 SEC 提交與交易相關的代理聲明。代理聲明將發送給截至投票交易的適用記錄日期的所有公司股東。公司還將向 SEC 提交與交易相關的其他文件。</p>
<p>在做出任何投票決定之前，建議股東閲讀代理聲明、任何修訂及所有其他與交易相關的相關文件，這些文件將在與交易相關時提交給 SEC，因為它們將包含關於公司和交易的重要信息。</p>
<p>投資者和股東可以通過 SEC 維護的網站 www.sec.gov 免費獲取代理聲明及公司向 SEC 提交的所有其他相關文件。公司向 SEC 提交的文件也可以在公司網站 http://jiuzhou360.com/investors/sec_filings 上免費獲取。</p>
<p>SEC 或任何州證券監管機構均未批准或不批准本通訊中描述的交易，未對交易或相關交易的優點或公平性進行評估，也未對本通訊中的披露的充分性或準確性進行評估。任何相反的陳述均構成刑事犯罪。</p>
<p><strong>無報價或招攬</strong></p>
<p>本新聞稿既不是代理的招攬，也不是購買要約或出售任何證券的招攬，也不是任何可能在擬議交易進行時向 SEC 提交的代理聲明或其他文件的替代品。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p><strong>公司聯繫人：</strong></p>
<p>Frank Zhao</p>
<p>首席財務官</p>
<p>+86-571-88077108</p>
<p>frank.zhao@jojodrugstores.com</p>
<p><strong>投資者關係聯繫人：</strong></p>
<p>Tina Xiao</p>
<p>Ascent Investor Relations LLC</p>
<p>+1-646-932-7242</p>
<p>investors@ascent-ir.com</p>
<p>來源：中國九洲大藥房股份有限公司</p>

九洲大藥房

RDGT

<p>中國九洲大藥房（Nasdaq:CJJD）宣佈進行戰略重組，專注於其批發業務，以提高盈利能力。這包括收購 Allright（杭州）互聯網科技有限公司，並將其零售業務出售給現任首席執行官劉雷和董事李琦。交易預計將在 2025 年第一季度完成，待股東批准。重組後，Frank Zhao 將擔任臨時首席執行官。公司旨在通過這一轉型提高運營效率，為股東創造長期價值</p>

<p>, /PRNewswire/ --China Jo-Jo Drugstores, Inc. (Nasdaq:CJJD) (&#34;Jo-Jo Drugstores&#34; or the &#34;Company&#34;), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announcedit has entered into definitive agreements for a strategic restructuring initiative to transition into an asset-light, wholesale-focused company, streamlining operations and enhancing profitability.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 中國九洲大藥房公司（Nasdaq:CJJD）（&#34;九洲大藥房&#34;或&#34;公司&#34;）是一家領先的線上和線下零售商、藥品及其他健康產品的批發分銷商以及中國的醫療服務提供者，今天宣佈已達成戰略重組計劃的最終協議，以轉型為輕資產、以批發為重點的公司，精簡運營並提升盈利能力。</p>
</div><p>The restructuring involved two major transactions (the &#34;Transactions&#34;):</p>
<div class="lb-trans"><p>此次重組涉及兩項主要交易（&#34;交易&#34;）：</p>
</div><ul>
<li>Acquisition transaction: The acquisition of Allright (Hangzhou) Internet Technology Co. Ltd. (&#34;Allright&#34;), a fast-growing company engaged in the pharmaceutical wholesale business, through an equity exchange for the issuance of 2,225,000 ordinary shares, which represents 38% of issued and outstanding ordinary shares of the Company after giving effect to the Transactions; and</li>
<li>Divestiture transaction: The sale of Jo-Jo Drugstores' drug retail business to Lei Liu, the current CEO and a director, and Li Qi, a director of the Company, who, together with their affiliates, currently owns approximately 41% of outstanding ordinary shares of the Company, in exchange for a surrender to the Company all shares held by Liu, Qi and their affiliates in the Company totaling 2,548,353 ordinary shares.</li>
</ul>
<div class="lb-trans"><ul>
<li>收購交易：通過發行 2,225,000 股普通股進行股權交換，收購快速成長的藥品批發公司 Allright（杭州）互聯網科技有限公司（&#34;Allright&#34;），這代表了交易完成後公司已發行和流通普通股的 38%；以及</li>
<li>剝離交易：將九洲大藥房的藥品零售業務出售給現任首席執行官兼董事劉雷和董事李琦，他們及其關聯方目前共同持有公司約 41% 的流通普通股，作為交換，劉、琦及其關聯方將向公司交回其持有的共計 2,548,353 股普通股。</li>
</ul>
</div><p>The Transactions are expected to close during the first quarter of 2025, subject to customary closing conditions, including approval by the shareholders of Jo-Jo Drugstores.Following the closing of the Transactions, Liu and Qi are expected to resign from the Board and any other position (including the CEO) of the Company, and the ultimate shareholder of Allright, Lingtao Kong, will join the Board. The parties agree that Frank Zhao, the Company's current CFO, will assume the role of interim CEO to ensure the continued operation of the business and integration of Allright's business.</p>
<div class="lb-trans"><p>預計交易將在 2025 年第一季度完成，需滿足包括九洲大藥房股東批准在內的慣常成交條件。交易完成後，劉和琦預計將辭去公司董事會及其他任何職務（包括首席執行官），而 Allright 的最終股東孔靈濤將加入董事會。各方同意，公司的現任首席財務官趙峯將擔任臨時首席執行官，以確保業務的持續運營和 Allright 業務的整合。</p>
</div><p>Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, &#34;This restructuring marks a pivotal moment for CJJD as we transition from a high-cost retail segment to a wholesale-focused model. While I will be shifting my focus to the retail business, an area where I have deep expertise, I believe this transformation will enhance operational efficiency and create long-term value for CJJD's shareholders. I look forward to seeing the wholesale business thrive under the new leadership.&#34;</p>
<div class="lb-trans"><p>九洲大藥房董事長兼首席執行官劉雷先生評論道：&#34;此次重組標誌着 CJJD 的一個關鍵時刻，我們將從高成本的零售領域轉型為以批發為重點的模式。雖然我將把重心轉向我深耕的零售業務，但我相信這一轉型將提升運營效率，併為 CJJD 的股東創造長期價值。我期待在新領導下看到批發業務蓬勃發展。&#34;</p>
</div><p>Mr. Lingtao Kong, the ultimate shareholder of Allright and incoming board member, stated, &#34;I am excited to join forces with CJJD as we build a stronger wholesale platform. Allright's growth trajectory aligns well with CJJD's strategic vision, and I am confident that our combined expertise will create new opportunities for expansion and success in the pharmaceutical wholesale market.&#34;</p>
<div class="lb-trans"><p>Allright 的最終股東及即將加入董事會的孔靈濤先生表示：&#34;我很高興能與 CJJD 攜手共建更強大的批發平台。Allright 的增長軌跡與 CJJD 的戰略願景高度契合，我相信我們的專業結合將為藥品批發市場創造新的擴展和成功機會。&#34;</p>
</div><p>Mr. Frank Zhao, the current CFO and incoming interim CEO, added, &#34;I am honored to take on this role as interim CEO during this transformative period. I want to thank Mr. Liu for his leadership and dedication in building CJJD into the strong company it is today. As we transition to a wholesale-driven model, I look forward to working closely with Mr. Kong and our team to execute our strategic vision and ensure a seamless integration of Allright's business. Our focus will remain on strengthening our wholesale operations, improving efficiency, and positioning CJJD for long-term success.&#34;</p>
<div class="lb-trans"><p>現任首席財務官及即將擔任臨時首席執行官的趙峯先生補充道：&#34;在這個轉型時期，我很榮幸能擔任臨時首席執行官。我想感謝劉先生在將 CJJD 建設成今天這樣強大公司的領導和奉獻。隨着我們向以批發為驅動的模式轉型，我期待與孔先生及我們的團隊緊密合作，執行我們的戰略願景，確保 Allright 業務的無縫整合。我們的重點將繼續放在加強批發業務、提高效率，併為 CJJD 的長期成功奠定基礎。&#34;</p>
</div><p><strong>AboutChina Jo-JoDrugstores, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於中國九洲大藥房公司</strong></p>
</div><p>China Jo-JoDrugstores, Inc. (&#34;Jo-Jo Drugstores&#34; or the &#34;Company&#34;), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services inChina. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visithttp://jiuzhou360.com. The Company routinely posts important information on its website.</p>
<div class="lb-trans"><p>中國九洲大藥房公司（&#34;九洲大藥房&#34;或&#34;公司&#34;）是一家領先的線上和線下零售商及藥品和其他健康產品的批發分銷商，同時也是中國的醫療服務提供者。九洲大藥房目前運營着一家在線藥房和零售藥店，現場有持證醫生提供諮詢、檢查和常見疾病的治療。它也是類似於其藥房所銷售產品的批發分銷商。有關公司的更多信息，請訪問 http://jiuzhou360.com。公司定期在其網站上發佈重要信息。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in press release, including statements regarding the benefits of the proposed Transactions and the anticipated timing of the completion of the proposed Transactions, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including &#34;may,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;believe,&#34; &#34;predict,&#34; &#34;plan,&#34; &#34;targets,&#34; &#34;projects,&#34; &#34;could,&#34; &#34;would,&#34; &#34;will,&#34; &#34;continue,&#34; &#34;forecast&#34; or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company's ability to complete the Transactions in a timely manner or at all, its ability to implement its business plans and strategies, its ability to raise additional funding, its ability to maintain and grow its business, fluctuations in wholesale pricing and demand for pharmaceutical products, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, its relationships with suppliers and healthcare providers, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other risk factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission (the &#34;SEC&#34;).</p>
<div class="lb-trans"><p>本新聞稿包含關於公司未來預期、計劃和前景的信息，這些信息構成了 1995 年美國私人證券訴訟改革法案、1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條所定義的前瞻性聲明。新聞稿中除歷史事實聲明外的所有聲明，包括關於擬議交易的好處和預計完成時間的聲明，均為前瞻性聲明。這些前瞻性聲明中的一些可以通過使用前瞻性詞彙來識別，包括 “可能”、“應該”、“期望”、“打算”、“將”、“估計”、“預期”、“相信”、“預測”、“計劃”、“目標”、“項目”、“可以”、“會”、“將”、“繼續”、“預測” 或這些術語的否定形式或變體或類似表達。所有前瞻性聲明均基於估計、預測和假設，儘管公司及其管理層認為這些是合理的，但本質上是不確定的。實際結果可能因多種因素而與歷史結果或這些前瞻性聲明所指示的結果有重大差異，包括但不限於與公司及時完成交易或根本無法完成交易的能力、實施其商業計劃和戰略的能力、籌集額外資金的能力、維持和發展其業務的能力、批發定價和藥品需求的波動、經營結果的變化、維持和提升品牌的能力、新產品和服務的開發和推出、成功整合收購的公司、技術和資產到其產品和服務組合中的能力、市場營銷和其他業務發展舉措、與供應商和醫療服務提供者的關係、行業競爭、一般政府監管、經濟狀況、對關鍵人員的依賴、吸引、招聘和留住具備滿足客户要求的技術技能和經驗的人員的能力，以及保護其知識產權的能力。公司鼓勵您查看可能影響其未來結果的其他風險因素，這些因素在公司的年度報告和向證券交易委員會（“SEC”）的其他文件中有所披露。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not any assurance that the post-combination company will achieve its expected results. The Company does not undertakes any duty to update these forward-looking statements, except as otherwise required by law.</p>
<div class="lb-trans"><p>您不應對前瞻性聲明過度依賴，這些聲明僅在作出時有效。公司不保證合併後的公司將實現其預期結果。除法律另有要求外，公司不承擔更新這些前瞻性聲明的義務。</p>
</div><p><strong>Important Information About the Proposed Transactions and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>關於擬議交易的重要信息及獲取途徑</strong></p>
</div><p>This press release relates to certain proposed Transactions involving Jo-Jo Drugstores. The Company will file a proxy statement with the SEC in connection with the Transactions. A proxy statement will be sent to all Company shareholders as of the applicable record date established for voting on the Transactions. The Company will also file other documents regarding the Transactions with the SEC.</p>
<div class="lb-trans"><p>本新聞稿涉及與九洲大藥房相關的某些擬議交易。公司將向 SEC 提交與交易相關的代理聲明。代理聲明將發送給截至投票交易的適用記錄日期的所有公司股東。公司還將向 SEC 提交與交易相關的其他文件。</p>
</div><p>Before making any voting decision, shareholders are urged to read the proxy statement, any amendments thereto, and all other relevant documents filed or that will be filed with the SEC in connection with the Transactions as they become available because they will contain important information about the Company and the Transactions.</p>
<div class="lb-trans"><p>在做出任何投票決定之前，建議股東閲讀代理聲明、任何修訂及所有其他與交易相關的相關文件，這些文件將在與交易相關時提交給 SEC，因為它們將包含關於公司和交易的重要信息。</p>
</div><p>Investors and shareholders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by the Company through the website maintained by the SEC at www.sec.gov. The documents filed by the Company with the SEC also may be obtained free of charge at the Company's website at http://jiuzhou360.com/investors/sec_filings.</p>
<div class="lb-trans"><p>投資者和股東可以通過 SEC 維護的網站 www.sec.gov 免費獲取代理聲明及公司向 SEC 提交的所有其他相關文件。公司向 SEC 提交的文件也可以在公司網站 http://jiuzhou360.com/investors/sec_filings 上免費獲取。</p>
</div><p>NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS COMMUNICATION, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.</p>
<div class="lb-trans"><p>SEC 或任何州證券監管機構均未批准或不批准本通訊中描述的交易，未對交易或相關交易的優點或公平性進行評估，也未對本通訊中的披露的充分性或準確性進行評估。任何相反的陳述均構成刑事犯罪。</p>
</div><p><strong>No Offer or Solicitation</strong></p>
<div class="lb-trans"><p><strong>無報價或招攬</strong></p>
</div><p>This press release is neither a solicitation of a proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the proposed Transactions proceed.</p>
<div class="lb-trans"><p>本新聞稿既不是代理的招攬，也不是購買要約或出售任何證券的招攬，也不是任何可能在擬議交易進行時向 SEC 提交的代理聲明或其他文件的替代品。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司聯繫人：</strong></p>
</div><p>Frank Zhao</p>
<div class="lb-trans"><p>Frank Zhao</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席財務官</p>
</div><p>+86-571-88077108</p>
<div class="lb-trans"><p>+86-571-88077108</p>
</div><p>frank.zhao@jojodrugstores.com</p>
<div class="lb-trans"><p>frank.zhao@jojodrugstores.com</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者關係聯繫人：</strong></p>
</div><p>Tina Xiao</p>
<div class="lb-trans"><p>Tina Xiao</p>
</div><p>Ascent Investor Relations LLC</p>
<div class="lb-trans"><p>Ascent Investor Relations LLC</p>
</div><p>+1-646-932-7242</p>
<div class="lb-trans"><p>+1-646-932-7242</p>
</div><p>investors@ascent-ir.com</p>
<div class="lb-trans"><p>investors@ascent-ir.com</p>
</div><p>SOURCE China Jo-Jo Drugstores, Inc.</p>
<div class="lb-trans"><p>來源：中國九洲大藥房股份有限公司</p>
</div>

China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth | CJJD Stock News

StockTitan

九洲大藥房宣佈戰略業務重組，以加強批發業務，實現更高的盈利和增長 | CJJD 股票新聞